PAULA JEAN KAPLAN-LEFKO, Ph.D.
Curriculum Vitae
PERSONAL HISTORY:
Business Address:
CURRENT POSITION:
Division of Hematology-Oncology
14-627 Factor Building
UCLA Medical Center
10833 Le Conte Ave.
Los Angeles, CA 90095
Phone: 310-206-2090
Fax: 310-206-2133
Email: pkaplanlefko@mednet.ucla.edu
Project Scientist
Department of Medicine, Division of Hematology/Oncology
UCLA, Los Angeles, CA
EDUCATION:
1983-1988
B.A. (Biology)
Scripps College, Claremont, CA
1985-1986
Study Abroad
Hebrew University, Jerusalem, Israel
1989-1996
Ph.D. (Biology)
Tufts University, Medford, MA
1996-2002
Postdoctoral Fellowship
Baylor College of Medicine, Houston, TX
PROFESSIONAL EXPERIENCE:
1988-1989
Research Technician/Clinical Technician
Cytometrics, San Diego, CA
2002-2005
Research Scientist I, Oncology Research
Amgen, Inc., Thousand Oaks, CA
2005-2009
Senior Scientist, Oncology Research
Amgen, Inc., Thousand Oaks, CA
2009-2011
Principal Scientist, Oncology Research
Amgen, Inc., Thousand Oaks, CA
Kaplan-Lefko CV 2015
July 2012-April 2013 Visiting Associate Researcher
Department of Medicine, Division of Hematology/Oncology
UCLA, Los Angeles, CA
April 2013-June 2014 Associate Researcher
Department of Medicine, Division of Hematology/Oncology
UCLA, Los Angeles, CA
July 2014 – present
Project Scientist
Department of Medicine, Division of Hematology/Oncology
UCLA, Los Angeles, CA
PROFESSIONAL ACTIVITIES:
Investigational New Drug (IND) Applications (Trials managing)
BB-IND 13859. Adoptive Transfer of MART-1 F5 TCR Engineered
Peripheral Blood Mononuclear Cells (PBMC) after a Non-myeloablative
Conditioning Regimen, with Administration of MART-126-35-Pulsed Dendritic
Cells and Interleukin-2, in Patients with Advanced Melanoma. UCLA IRB#
08-02-020/10-001212. Sponsor Ribas.
BB-IND 14760. MART-1 F5 TCR Engineered Adoptive Cell Transfer
Therapy with CTLA4 Blockade. IRB#12-000164. Sponsor Ribas.
BB-IND 15167. Adoptive Transfer of NY-ESO-1 TCR Engineered Peripheral
Blood Mononuclear Cells (PBMC) after a Nonmyeloablative Conditioning
Regimen, with Administration of NY-ESO-1157-165 Pulsed Dendritic Cells and
Interleukin-2, in Patients with Advanced Malignancies. IRB#12-000153.
Sponsor Ribas.
BB-IND 15167. NY-ESO-1TCR Engineered Adoptive Cell Transfer Therapy
with CTLA4 Blockade. IRB#13-001624. Sponsor Ribas.
IND pending. Studies of Immunogenicity of Intralesional Injection of
Talimogene Laherparepvec (T-Vec) in Patients with Melanoma.
IRB#pending. Sponsor Ribas.
IND pending. Biomarkers of durable response with intermittent therapy with
LGX818 and MEK162 combined therapy in patients with BRAF mutant
metastatic melanoma. IRB#pending. Sponsor Ribas.
IND pending. Adoptive Transfer of MART-1 F5 TCR/sr39TK Engineered
Peripheral Blood Mononuclear Cells (PBMC) after a Nonmyeloablative
Conditioning Regimen, with Administration of MART-126·35-Pulsed Dendritic
2
Kaplan-Lefko CV 2015
Cells and Interleukin-2, in Patients with Advanced Melanoma. IRB # pending.
Sponsor Ribas.
Pre-IND. Adoptive Transfer of NY-ESO-1 TCR Engineered Peripheral Blood
Mononuclear Cells (PBMC) and Hematopoietic Stem Cells (HSC) after a
Nonmyeloablative Conditioning Regimen, with Administration of Interleukin2, in Patients with Advanced Malignancies. Sponsor Ribas.
Preclinical Toxicology Protocols Written in Support of Future Clinical Trial
(Pre-IND)
Title: Effects of Co-Administration of NY-ESO-1 TCR genetically modified T
cells and HSCs in HLA-A2.1/Kb mice; Role: Project Manager
Title: In Vivo Assessment of Suicide Gene Function of sr39TK Transgene in
RRL-MSCVoptNYESOoptsr39TK Lentiviral Vector Transduced Human
HSPCs
Title: In Vitro Assessment of the Insertional Immortalization Activity of the
NY-ESO1 TCR/sr39TK Lentiviral Vector; Role: Project Manager
Title: Assessment of Immunogenicity of Administration of NY-ESO-1
TCR/sr39TK genetically modified HSCs in HLA-A2.1/Kb Mice; Role:
Project Manager
Title: In Vivo Assessment of the Insertion Profile of the
NY-ESO1 TCR/sr39TK Lentiviral Vector; Role: Project Manager
Teaching Experience
Fall 1989, 1991, 1993 Graduate Teaching Assistant in Introductory Biology course
and laboratory, Tufts University, Department of Biology,
Medford, MA
Spring 1990
Graduate Teaching Assistant in Experiments in Biology
laboratory, Tufts University, Department of Biology, Medford,
MA
Fall 1990
Graduate Teaching Assistant in Genetics course and laboratory,
Tufts University, Department of Biology, Medford, MA
Spring 1991
Graduate Teaching Assistant in Microbiology laboratory, Tufts
University, Department of Biology, Medford, MA
Spring 1993
Graduate Teaching Assistant in Endocrinology,
University, Department of Biology, Medford, MA
3
Tufts
Kaplan-Lefko CV 2015
2001
Teaching Assistant at the Techniques for Modeling Human
Cancer in Mice Workshop, The Jackson Laboratory, Bar
Harbor, ME
Mentoring/Supervising (Limited to UCLA)
2012
Aida Attar, Graduate Student, UCLA
2013
Steven Blum, Medical Student, UCLA
Zeynep Eroglu, Oncology Fellow, UCLA/City of Hope
Daniel Shin, Oncology Fellow, UCLA
Tiffany Moalemzadeh, Milken Community High School
Student
Angel Garcia Diaz, Post-doctoral Fellow, UCLA
2014
Tiffany Moalemzadeh, Milken Community High School
Student
Overseeing the following people in regulatory work related to
clinical trials:
Zeynep Eroglu, Oncology Fellow, UCLA/City of Hope
Daniel Shin, Oncology Fellow, UCLA
Andrea Hobby, Regulatory Coordinator, UCLA
Leading CIRM Disease Team Grant Group. Overseeing the
following people in studies to obtain FDA approval for our
proposed use of T cell receptor engineered hematopoietic stem
cells:
Angel Garcia Diaz, Post-doctoral Fellow, UCLA
Giulia Parisi, Post-doctoral Fellow, UCLA
Cristina Puig Saus, Post-doctoral Fellow, UCLA
Paige Krystofinski, Staff Research Associate, UCLA
Ruixue Zhang, Staff Research Associate, UCLA
Overseeing the following people in the manufacturing of
clinical grade gene modified cells:
Beata Berent Maoz, Project Scientist, UCLA
Rongqing Guo, Staff Research Associate, UCLA
Jia Pang, Staff Research Associate, UCLA
2015
Sofia Martinez, Volunteer, UCLA
4
Kaplan-Lefko CV 2015
Community Service
1991
Organized the Department of Biology seminar series, Tufts
University, Medford, MA
1991-1993
Group leader for the teaching assistant orientation, Tufts
University, Medford, MA
1992-1994
Dept. of Biology representative to the Graduate Student
Council, Tufts University, Medford, MA
1992-1994
Dept. of Biology graduate student orientation committee, Tufts
University, Medford, MA
1997-2002
Baylor College of Medicine Postdoctoral Association member,
Houston, TX
2000-2001
Participant, Steinberg Leadership Institute, Anti-Defamation
League, Houston, TX
2004
Participated in an elementary school career day, Los Angeles,
CA
2007
Presented at the Amgen new hire orientation, Thousand Oaks,
CA
2007
Panel member representing Amgen in 2 High School Science
and Technology Showcases, Westlake Village and Newbury
Park, CA
2009, 2008
Discussion leader and panelist in the Amgen Scholar Program,
UCLA, Los Angeles, CA
2012
Contributed articles to the Southern California American
Medical Writers Association (AMWA) chapter newsletter
2012-present Electronic case report form (eCRF) development committee for
investigator-initiated clinical trials, UCLA
2015-present Member of the Institutional Biosafety Committee (IBC)
Faculty/Researcher Advisory Committee, UCLA
Professional Associations
1992-present Women in Cancer Research
5
Kaplan-Lefko CV 2015
1992-present American Association for Cancer Research
1997-2002
Society for Basic Urologic Research
1998-2002
IGF Society
1998-2002
Endocrine Society
2011-present American Medical Writers Association
Editorial Services
2000-2002
Reviewer for Urology
2000-2002
Reviewer for The Journal of Urology
2005
Reviewer for Clinical Cancer Research
2005
Reviewer for Journal of Biological Chemistry
2007
Reviewer for Cancer Research
2007
Reviewer for Molecular Therapeutics
2007
Reviewer for Gynecologic Oncology
Patents
May 5, 2011 Teresa Burgess, Angela
Kaplan-Lefko, Anthony
Combinations VEGF (R)
Factor (c-Met) Inhibitors
2011/0104161 A1.
Coxon, Isabelle Dussault, Paula
Polverino and Darrin Beaupre.
Inhibitors and Hepatocyte Growth
for the Treatment of Cancer. US
HONOR AND SPECIAL AWARDS
1992
International Symposium on Biology of Prostate Growth,
Travel Award
1993, 1989-1991
Teaching Fellowship, Tufts University, Medford, MA
1994, 1993
Graduate School of Arts and Science, Travel Award, Medford,
MA
1994-1996, 1992
Research Fellowship, Tufts University, Medford, MA
6
Kaplan-Lefko CV 2015
1997, 1995, 1993
Gordon Research Conference on Hormonal Carcinogenesis,
Travel Award
1998
AACR Molecular Biology of Neoplasia Workshop, Participant
1999
International Symposium on Insulin-like Growth Factors,
Travel Award
RESEARCH GRANTS AND FELLOWSHIPS RECEIVED
1997-2000
National Cancer Institute, National Research Service Award,
CA74589. Title: IGF in Prostate Cancer: A Transgenic
Study. Principle Investigator. $93,948
1999-2004
National Institutes of Health, Biochemical Endocrinology
Study Section, R01, CA82807. Title: IGF Axis in Prostate
Cancer: A Transgenic Study. Co-authored with postdoc
advisor, Norman Greenberg. $1,335,180
2000-2003
Association for the Cure of Cancer of the Prostate (CaP
CURE), Young Investigator Award. Title: Abrogation of
IGF1R as Therapy for Prostate Cancer. Principle Investigator.
$150,000
LECTURES AND PRESENTATIONS
Spring 1993, 1992
Tufts University, Department of Biology, Medford, MA
Howard Hughes Foundation Teaching Scholar
Program; Prepared and presented lectures in
Endocrinology 110 on the topics of peptide hormone
action, growth factors, male reproduction and sex
differentiation under the guidance of department faculty
Spring 1995, 1994, 1993
Tufts University, Department of Biology, Medford, MA
Guest lecturer for Endocrinology 110; Title: Peptide
hormone action
1995
Harvard University, Department of Urology, Children’s
Hospital, Boston, MA; Title: Involvement of the EGF
family in hormonally induced prostatic dysplasia
1999
MD Anderson Cancer Center, Houston,
Genitourinary Oncology Seminar Series; Title:
IGF axis in prostate cancer
7
TX.
The
Kaplan-Lefko CV 2015
1999
Baylor College of Medicine, Department of Cell
Biology Reproduction & Development Workshop,
Houston, TX; Title: The IGF axis in prostate cancer
1999
MD Anderson Cancer Center, Houston, TX.
Thoracic/Head and Neck Medical Oncology Seminar
Series; Title: The IGF axis in prostate cancer
1999
MD Anderson Cancer Center, Division of Cancer
Prevention Seminar Series, Houston, TX.
Title:
Changes in the insulin-like growth factor axis in
prostate cancer using transgenic animal models
2000
Baylor College of Medicine, Urology Grand Rounds,
Houston, TX. Title: Insulin-like growth factor axis in
prostate cancer
2007
University of California at Santa Barbara, Guest
lecturer for Pharmacology course. Title: The Use of
Preclinical Models in Drug Development
2014
University of Southern California, Guest lecturer for
RSCI606 Regulation of Emerging Technologies and
Biological Products. Title: Gene Therapy:
Regulations and Current Status
8
Kaplan-Lefko CV 2015
RESEARCH PAPERS
PEER-REVIEWED (PUBLISHED)
1. Ghatak, S, Oliveria, P, Kaplan, P and Ho, S-M. 1996. Expression and regulation of
metallothionein mRNA levels in the prostates of Noble rats: Lack of expression in the
ventral prostate and regulation by sex hormones in the dorsolateral prostate. The Prostate.
29:91-100.
2. Kaplan, PJ, Leav, I, Greenwood, J, Kwon, PWL and Ho, S-M. 1996. Involvement of
transforming growth factor α (TGFα) and epidermal growth factor receptor (EGFR) in sex
hormone-induced prostatic dysplasia and the growth of an androgen-independent
transplantable carcinoma of the prostate. Carcinogenesis. 17:2571-2579.
3. Foster, BA, Kaplan, PJ and Greenberg, NM. 1999. Characterization of the FGF axis and
identification of a novel FGFR1iiic isoform during prostate cancer progression in the
TRAMP model. Prostate Cancer and Prostatic Diseases. 2:76-82.
4. Kaplan, PJ, Mohan, S, Cohen, P, Foster, BA and Greenberg, NM. 1999. The IGF axis
and prostate cancer: Lessons from TRAMP. Cancer Research. 59:2203-2209.
5. Foster, BA, Evangelou, A, Gingrich, JR, Kaplan, PJ, DeMayo, F and Greenberg, NM.
2002. Enforced expression of FGF-7 promotes epithelial hyperplasia whereas a dominant
negative FGFR2iiib promotes the emergence of neuroendocrine phenotype in prostate glands
of transgenic mice. Differentiation. 70(9-10):624-632.
6. Uzgare, AR, Kaplan, PJ and Greenberg, NM. 2003. Differential expression and
activation of p38 MAPK, Erk 1/2 and Jnk during the initiation and progression of prostate
cancer. Prostate. 55(2):128-139.
7. Kaplan-Lefko, PJ, Chen, TM, Maddison, LA, Huss, WJ, Barrios, R, Ittman, M, Ayala, G
and Greenberg, NM. 2003. Pathobiology of autochthonous prostate cancer in a transgenic
mouse model. Prostate. 55(3):219-237.
8. Majeed N, Blouin MJ, Kaplan-Lefko PJ, Barry-Shaw J, Greenberg NM, Gaudreau P,
Bismar TA, Pollak M. 2005. A germ line mutation that delays prostate cancer progression
and prolongs survival in a murine prostate cancer model. Oncogene. 24:4736-40.
9. Morgenbesser SD, McLaren RP, Richards B, Zhang M, Akmaev VR, Winter SF, Mineva
ND, Kaplan-Lefko PJ, Foster BA, Cook BP, Dufault MR, Cao X, Wang CJ, Teicher BA,
Klinger KW, Greenberg NM, Madden SL. 2007. Identification of genes potentially
involved in the acquisition of androgen-independent and metastatic tumor growth in an
autochthonous genetically engineered mouse prostate cancer model. Prostate. 67:83-106.
10. Kaplan-Lefko PJ, Sutherland BW, Evangelou AI, Hadsell DL, Barrios RJ, Foster BA,
DeMayo F and Greenberg NM. 2008. Enforced epithelial expression of IGF-1 causes
9
Kaplan-Lefko CV 2015
hyperplastic prostate growth while negative selection is requisite for spontaneous
metastogenesis. Oncogene. 27:2868-76.
11. Bellon SF, Kaplan-Lefko P, Yang Y, Zhang Y, Moriguchi J, Rex K, Johnson CW, Rose
PE, Long AM, O'Connor AB, Gu Y, Coxon A, Kim TS, Tasker A, Burgess TL, Dussault I.
2008. c-Met inhibitors with novel binding mode show activity against several hereditary
papillary renal cell carcinoma-related mutations. J Biol Chem. 283:2675-83.
12. Albrecht BK, Harmange JC, Bauer D, Berry L, Bode C, Boezio AA, Chen A, Choquette
D, Dussault I, Fridrich C, Hirai S, Hoffman D, Larrow JF, Kaplan-Lefko P, Lin J, Lohman
J, Long AM, Moriguchi J, O’Connor A, Potashman MH, Reese M, Rex K, Siegmund A,
Shah K, Shimanovich R, Springer SK, Teffera Y, Yang Y, Zhang Y and Bellon SF. 2008.
Discovery and optimization of triazolopyridazines as potent and selective inhibitors of the cMet kinase. J Med Chem. 51:2879-82.
13. Sutherland BW, Knoblaugh SE, Kaplan-Lefko PJ, Wang F, Holzenberger M and
Greenberg NM. 2008. Conditional deletion of IGF1R in prostate epithelium. Cancer Res.
68:3495-3504.
14. Liu L, Siegmund A, Xi N, Kaplan-Lefko P, Rex K, Chen A, Lin J, Moriguchi J, Berry
L, Huang L, Teffera Y, Yang Y, Zhang Y, Bellon SF, Lee M, Shimanovich R, Bak A,
Dominguez C, Norman MH, Harmange JC, Dussault I and Kim TS. 2008. Discovery of a
potent, selective, and orally bioavailable c-Met inhibitor: AMG 458. J Med Chem. 51:368891.
15. Zhang Y, Kaplan-Lefko PJ, Rex K, Yang Y, Moriguchi J, Osgood T, Mattson B,
Coxon A, Reese M, Kim TS, Lin J, Chen A, Burgess TL and Dussault I. 2008.
Identification of a novel recepteur d’origine nantais/c-Met small-molecule kinase inhibitor
with antitumor activity in vivo. Cancer Res. 68:6680-6687.
16. D’Angelo ND, Bellon SF, Booker SK, Cheng Y, Coxon A, Dominguez C, Fellows I,
Hoffman D, Hungate R, Kaplan-Lefko P, Lee MR, Li C, Liu L, Rainbeau E, Reider PJ, Rex
K, Siegmund A, Sun Y, Tasker AS, Xi N, Xu S, Yang Y, Zhang Y, Burgess TL, Dussault I
and Kim TS. 2008. Design, synthesis, and biological evaluation of potent c-Met inhibitors.
J. Med. Chem. 51:5766-5779.
17. Boezio AA, Berry L, Albrecht BK, Bauer D, Bellon SF, Bode C, Chen A, Choquette D,
Dussault I, Fang M, Hirai S, Kaplan-Lefko P, Larrow JF, Lin MH, Lohman J, Potashman
MH, Qu Y, Rex K, Santostefano M, Shah K, Shimanovich R, Springer SK, Teffera Y, Yang
Y, Zhang Y, Harmange JC. 2009. Discovery and optimization of potent and selective
triazolopyridazine series of c-Met inhibitors. Bioorg Med Chem Lett. 19:6307-12.
18. Gordon MS, Sweeney CS, Mendelson DS, Eckhardt SG, Anderson A, Beaupre DM,
Branstetter D, Burgess TL, Coxon A, Deng H, Kaplan-Lefko P, Leitch IM, Oliner KS, Yan
L, Zhu M and Gore L. Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a
10
Kaplan-Lefko CV 2015
fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human
study of patients with advanced solid tumors. 2010. Clin Cancer Res. 16:699-710.
19. Zoog SJ, Ma CY, Kaplan-Lefko PJ, Hawkins JM, Moriguchi J, Zhou L, Pan Y, Hsu
CP, Friberg G, Herbst R, Hill J and Juan G. 2010. Measurement of conatumumab-induced
apoptotic activity in tumors by fine needle aspirate sampling. Cytometry A. 77:849-60.
20. Kaplan-Lefko PJ, Graves JD, Zoog SJ, Pan Y, Wall J, Branstetter DG, Moriguchi J,
Coxon A, Huard JN, Xu R, Peach ML, Juan G, Kaufman S, Chen Q, Bianchi A, Kordich JJ,
Ma M, Foltz IN and Gliniak BC. 2010. Conatumumab, a fully human agonist antibody to
death receptor 5, induces apoptosis via caspase activation in multiple tumor types. Cancer
Biol Ther. 9:618-31.
21. Rossin R, Kohno T, Hagooly A, Sharp T, Gliniak B, Arroll T, Chen Q, Hewig A,
Kaplan-Lefko P, Friberg G, Radinsky R, Evelhoch JL, Welch MJ, Hwang DR. 2011.
Characterization of 64Cu-DOTA-conatumumab: a PET tracer for in vivo imaging of death
receptor 5. J Nucl Med. 52:942-9.
22. Chodon T, Comin-Anduix B, Chmielowski B, Koya K, Wu Z, Allen-Auerbach M, Ng C,
Avramis E, Seja E, Villanueva A, McCannel T, Ishiyama A, Czernin J, Radu C, Wang X,
Gjertson D, Cochran A, Cornetta K, Wong D, Kaplan-Lefko P, Hamid O, Samlowski W,
Cohen P, Daniels G, Mukherji B, Yang L, Zack J, Kohn D, Heath J, Glaspy J, Witte O,
Baltimore D, Economou J and Ribas A. 2014. Adoptive transfer of MART-1 T cell receptor
transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma.
Clin Cancer Res. 20:2457-65.
23. Payton M, Jun H, Wayne W, Yu D, Manoukian R, Chung G, Zhang L, Sun J-R, KaplanLefko P, Radinsky R, Kendall R, Oliner J and Coxon A. 2014. Antagonism of angiopoietinTie2 and Dll4-Notch signaling mediate distinct and opposing effects on tumor-associated
endothelial cell proliferation. Lab Invest. 94: 12-96-1308.
RESEARCH PAPERS – PEER REVIEWED (IN PRESS)
None
RESEARCH PAPERS – PEER REVIEWED (SUBMITTED)
None
RESEARCH PAPERS – NON-PEER-REVIEWED
None
CHAPTERS
None
11
Kaplan-Lefko CV 2015
LETTERS TO THE EDITOR
None
REVIEWS
1. Foster, B.A., Kaplan, P.J. and Greenberg, N.M. 1999. Peptide growth factors and
prostate cancer: New models, new opportunities. Cancer and Metastasis Reviews. 17:317324.
2. Dussault I, Kaplan-Lefko P, Jun T, Coxon A, Burgess TL. 2006. HGF- and c-Mettargeted drugs: hopes, challenges and their future in cancer therapy. Drugs of the Future.
31:819-825.
3. Jun HT, Stevens J and Kaplan-Lefko P. 2008. Top NOTCH Targets: Notch Signaling in
Cancer. Drug Development Research. 69:319-328.
EDITORIALS
None
PAPERS IN PREPARATION
None
ABSTRACTS
1. Kaplan, P. and Ho, S-M. 1992. A possible role of EGFR in mediating a steroid-induced
prostatic dysplasia. International Symposium on Biology of Prostate Growth, Bethesda, MD.
2. Kaplan, P. and Ho, S-M. 1993. Possible involvement of TGFα and its receptor in the
progression of a hormonally induced adenocarcinoma in the rat dorsolateral prostate.
Gordon Research Conference on Hormonal Carcinogenesis, Newport, RI.
3. Kaplan, P., Montana, J., and Ho, S-M. 1994. Involvement of the TGFα/EGF receptor in
the induction and development of prostatic dysplasia and carcinoma in Noble rats treated
with testosterone and estradiol. American Association for Cancer Research Annual Meeting.
35, abstract # 1561, p. 261.
4. Kaplan, P., Greenwood, J., Montana, J. and Ho, S-M. 1994. Activation of the
transforming growth factor alpha/epidermal growth factor receptor signal transduction
pathway in precancerous and cancerous rat prostatic tissues. New England Endocrinology
Conference, Durham, NH.
12
Kaplan-Lefko CV 2015
5. Kaplan, P., Montana, J. and Ho, S-M. 1995. Enhanced expression of TGFα and EGF
receptor in rat prostatic dysplasia and carcinoma. American Association for Cancer
Research Annual Meeting. 36, abstract #1594, p. 267.
6. Kaplan, P., Hadsell, D., DeMayo, F., Rosen, J. and Greenberg, N. 1997. Deregulated
IGF expression in the prostate of transgenic mice. American Association for Cancer
Research Annual Meeting. 38, abstract #2813, p. 420.
7. Kaplan, P., Hadsell, D., DeMayo, F., Rosen, J. and Greenberg, N. 1997. Deregulated
IGF expression in the prostate of transgenic mice. Gordon Research Conference on
Hormonal Carcinogenesis, Tilton, NH.
8. Kaplan, P., Hadsell, D.L., Rosen, J.M. and Greenberg, N.M. 1997. Transgenic
deregulation of IGF expression in the prostate. M.D. Anderson Symposium on Fundamental
Cancer Research, Houston, TX.
9. Kaplan, P. and Greenberg, N.M. 1998. IGF expression during prostate cancer
progression in TRAMP mice. American Association for Cancer Research Annual Meeting.
39, abstract #749, New Orleans, LA.
10. Kaplan, P.J., Hadsell, D.L., Rosen, J.M. and Greenberg, N.M. 1998. Deregulated IGF
expression is associated with prostate cancer progression in transgenic mice. Molecular
Biology and Pathology of Neoplasia Workshop, American Association for Cancer Research,
Keystone, Co.
11. Kaplan, P.J., Huss, W.J., Hadsell, D.L., Rosen, J.M. and Greenberg, N.M. 1999.
Expression of prostatic DES-Insulin-like-growth factor I results in preneoplastic changes in
transgenic mice. Growth Hormone and IGF Research. 9, abstract #193, International
Symposium on Insulin-like Growth Factors, Brighton, England.
12. Kaplan, P., Barrios, R., Hadsell, D., Huss, W., Rosen, J. and Greenberg, N. 2000.
Deregulated IGF-I expression in the prostate of transgenic mice contributes to preneoplastic
changes. Society for Basic Urologic Research Fall Symposium, Ft. Myers, FL.
13. Kaplan, P., Barrios, R., Hadsell, D., Huss, W., Rosen, J. and Greenberg, N. 2000.
Deregulated IGF-I expression in the prostate of transgenic mice contributes to preneoplastic
changes. Mouse Models of Cancer, American Association for Cancer Research, La Jolla,
CA.
14. Choquette D, Harmange J-C, Kim T-S, Roveto P, Bellon S, Dussault I, Lin J, KaplanLefko P and Rex K. 2007. Pyridones: A new class of orally bioavailable and selective cMet inhibitors. Gordon Research Conference, Medicinal Chemistry.
15. Zhang Y, Kaplan-Lefko P, Rex K, Yang Y, Moriguchi J, Osgood T, Mattson B, Coxon
A, Burgess TL and Dussault I. 2007. Identification and characterization of a novel RON/c-
13
Kaplan-Lefko CV 2015
Met small molecule inhibitor. Molecular Targets and Cancer Therapeutics AACR-NCIEORTC International Conference, San Francisco, CA.
16. Bellon S, Kaplan-Lefko P, Yang Y, Zhang Y, Moriguchi J, Rex K, Johnson C, Coxon
A, Kim T-S, Tasker A, Burgess TL and Dussault I. 2007. C-Met inhibitors with novel
binding mode show activity against several HPRCC-related mutations.
American
Association for Cancer Research Annual Meeting, Los Angeles, CA.
17. Kaplan-Lefko P, Gan Y, Huard J, Colloton M, Zoog S, Juan G, Dobson T, Peach M,
Pan Y, Kaufman S, Branstetter D, Coxon A, Bianchi A, Wong-Madden S, Foltz I and
Gliniak B. 2007. AMG 655, a fully human agonistic antibody against TRAIL receptor-2,
induces apoptosis via caspase activation in vitro and in vivo. American Association for
Cancer Research Annual Meeting, Los Angeles, CA.
18. Bauer D, Albrecht B, Bellon S, Berry L, Bode C, Boezio A, Chen A, Choquette D,
Dussault I, Fridrich C, Hirai S, Larrow J, Kaplan-Lefko P, Lin J, Lohman J, Long A,
Moriguchi J, O’Connor A, Potashman M, Reese M, Rex K, Siegmund A, Shah K,
Shimanovitch R, Springer S, Teffera Y, Yang Y, Zhang Y and Harmange JC. 2008.
Discovery and optimization of a new series of potent and selective inhibitors of the c-Met
kinase. American Association for Cancer Research Annual Meeting, San Diego, CA.
19. Hagooly A, Rossin R, Kohno H, Gliniak B, Arroll T, Kaplan-Lefko P, Evelhoch J,
Welch M and Hwang D-R. 2008. Measuring DR5 occupancy in tumors using Cu64-DOTAAMG 655. SNM Annual Meeting, New Orleans, LA.
20. Hwang D-R, Rossin R, Gliniak B, Kohno H, Arroll T, Kaplan-Lefko P, Wiezorek J,
Friberg G, Radinsky R, Evelhoch JL and Welch MJ. 2008. PET measurement of DR5
receptor occupancy using Cu64-labelled AMG 655 in Colo 205 xenografts. American
Association for Cancer Research Annual Meeting, San Diego, CA.
21. Kaplan-Lefko P, Bush T, Belmontes B, Moriguchi J, Dansey M, Osgood T, Canon J,
Van Der Vuurst De Vries A-R, Graves J, Branstetter D, Coxon A and Gliniak B. 2008.
AMG 655, a fully human agonist antibody against death receptor 5, enhances the anti-tumor
activity of gemcitabine in MiaPaCa2/T2, a pancreatic cancer model. American Association
for Cancer Research Annual Meeting, San Diego, CA.
22. Connie Ma, Paula Kaplan-Lefko, Jenn Hawkins, Yang Pan, Matt Peach, Scott
Patterson, John Ferbas, Greg Friberg, John Hill, Gloria Juan, Stephen Zoog. 2009. Using
Fine Needle Aspirates to Quantitate Caspase-3 Activation in Tumors. AAPS National
Biotechnology Conference.
23. Kaplan-Lefko P*, Rex K*, Zhang Y, Yang Y, Kha H, Ziegler B, Moriguchi J, Mallari
M, Zhao X, Choquette D, Lewis, R Lin J, Shimanovich R, Broome M and Dussault I. 2011.
In Vitro and In Vivo Profiling of Class I and Class II ATP-Competitive c-Met Kinase
Inhibitors Defines Potential c-Met-Specific Sensitivity Biomarkers. American Association for
Cancer Resaerch Annual Meeting, Orlando, FL. *Contributed equally
14
Kaplan-Lefko CV 2015
24. Coxon A, Kaplan-Lefko P, Kaufman S, Moriguchi J, Sun J, Ziegler B, Wayne W,
Estrada J, Lavallee J, Park C, Arora T, Burgess T and Jun T. 2012. Inhibition of
angiopoietin and Dll4 signaling in the tumor vasculature leads to increased efficacy in mouse
tumor xenograft models. American Association for Cancer Research Annual Meeting,
Chicago, IL.
25. Bready JV, Kaplan-Lefko P, Moriguchi J, Payton M, Kaufman S, Oliner J, Radinsky R
and Coxon A. 2013. Combined treatment of trebananib (AMG 386) with panitumumab in
preclinical tumor models. American Association for Cancer Research Annual Meeting,
Washington, DC.
26. Hughes PE, Yang Y, Rex K, Zhang Y, Kaplan-Lefko PJ, Caenepeel S, Moriguchi J,
Broome M, Choquette D, Radinsky R, Kendall R, Coxon A and Dussault I. 2014. AMG
337, a novel, potent and selective MET kinase inhibitor, has robust growth inhibitory activity
in MET-dependent cancer models. American Association for Cancer Research Annual
Meeting, San Diego, CA.
ORAL PRESENTATIONS (Short talks at meetings)
1. Kaplan, P. and Ho, S-M. 1991. The role of growth factors in hormonally induced
prostatic dysplasia. New England Endocrinology Conference, Boston, MA
2. Kaplan, P.J., Mohan, S., Cohen, P., Hadsell, D.L., Rosen, J.M. and Greenberg, N.M.
1998. Deregulation of IGF-I contributes to progression prostate cancer while loss of IGF1R
is associated with metastatic and androgen independent disease. New Research Approaches
in the Prevention and Cure of Prostate Cancer, American Association for Cancer Research,
Indian Wells, CA.
3. Kaplan, P.J., Huss, W.J., Hadsell, D.L., Rosen, J.M. and Greenberg, N.M. 1999.
Deregulated prostatic IGF-I expression contributes to prostatic neoplasia in transgenic mice.
American Association for Cancer Research Annual Meeting.
40, abstract #2683,
Philadelphia, PA.
4. Kaplan, P.J., Barrios, R., Hadsell, D.L. and Greenberg, N.M. 2001. Deregulated IGF-I
expression in the prostate of transgenic mice exacerbates preneoplastic changes associated
with aging. Modeling Human Prostate Cancer in Mice Conference. The Jackson
Laboratory, Bar Harbor, ME.
5. Kaplan-Lefko, PJ. 2007. Animal Model Selection for Efficacy with Biologics for
Cancer. Biosafe General Membership Meeting, San Diego, CA.
6. Kaplan-Lefko P, Rex K, Moriguchi J, Yang Y, Zhang Y, Chen A, Lin J, Kaufman S, Kim
T-S, Liu L, Siegmund A, Harmange JC, Shimanovich R, Burgess T, Kendall R, Radinsky R,
Coxon A and Dussault I. 2008. AMG 458, a potent small molecule c- Met inhibitor, has
15
Kaplan-Lefko CV 2015
significant anti-tumor activity in vivo. American Association for Cancer Research Annual
Meeting, San Diego, CA.
16